Plasmepsin: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (15 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='350' side='right' caption='Plasmepsin II complex with a potential antimalarial drug (PDB entry [[4cku]])' scene='44/441867/Cv/1'> | |||
[[Plasmepsin]] (Plm) is a hemoglobin-degrading enzyme produced by the plasmodium parasite | == Function == | ||
[[Plasmepsin]] (Plm) is a hemoglobin-degrading enzyme produced by the plasmodium parasite. It is an aspartic acid protease having 2 aspartic acid residues in the active site. Ten Plm isoforms are known which are named Plm I, II, etc and '''Histo-Aspartic Protease (HAP)'''. | |||
< | *'''Proplasmepsin II''' exhibits a large shift between its domains which renders the protease inactive<ref>PMID:9886289</ref>. | ||
==Relevance == | |||
Plm is a potential target for anti-malaria drugs<ref>PMID:25719272</ref>. | |||
== Structural highlights == | |||
The active site of Plm II contains a <scene name='44/441867/Cv/4'>catalytic dyad of 2 Asp residues which interact with potential antimalarial inhibitor</scene><ref>PMID:24900843</ref>. <scene name='44/441867/Cv/5'>Whole active site</scene>. Water molecules are shown as red spheres. | |||
</StructureSection> | |||
==3D structures of plasmepsin== | ==3D structures of plasmepsin== | ||
| Line 11: | Line 18: | ||
*Histo-Aspartic Protease | *Histo-Aspartic Protease | ||
**[[3fns]], [[3qvc]] – PfHAP - ''Plasmodium falciparum''<br /> | **[[3fns]], [[3qvc]], [[6kub]], [[6kuc]], [[6kud]] – PfHAP - ''Plasmodium falciparum''<br /> | ||
**[[3fnt]] – PfHAP + pepstatin<br /> | **[[3fnt]] – PfHAP + pepstatin<br /> | ||
**[[3fnu]], [[3qvi]] – PfHAP + inhibitor<br /> | **[[3fnu]], [[3qvi]] – PfHAP + inhibitor<br /> | ||
| Line 25: | Line 32: | ||
**[[3f9q]] – PfPlm II (mutant)<br /> | **[[3f9q]] – PfPlm II (mutant)<br /> | ||
**[[2r9b]] – PfPlm II + peptide inhibitor<br /> | **[[2r9b]] – PfPlm II + peptide inhibitor<br /> | ||
**[[1w6h]], [[2bju]], [[1lf2]], [[1lf3]], [[1lee]], [[2igx]], [[2igy]], [[4cku]] – PfPlm II + inhibitor<br /> | **[[1w6h]], [[2bju]], [[1lf2]], [[1lf3]], [[1lee]], [[2igx]], [[2igy]], [[4cku]], [[4y6m]], [[4z22]], [[5yia]], [[5yib]], [[5yic]], [[5yid]], [[5yie]], [[7qyh]] – PfPlm II + inhibitor<br /> | ||
**[[4ya8]] – PfPlm II (mutant) + inhibitor<br /> | |||
**[[7ve0]], [[7ve2]] – PfPlm II + drug<br /> | |||
**[[1w6i]], [[1xdh]], [[1xe5]], [[1xe6]], [[1me6]], [[1sme]] – PfPlm II + pepstatin derivative<br /> | **[[1w6i]], [[1xdh]], [[1xe5]], [[1xe6]], [[1me6]], [[1sme]] – PfPlm II + pepstatin derivative<br /> | ||
**[[1m43]] - PfPlm II (mutant) + pepstatin derivative<br /> | **[[1m43]] - PfPlm II (mutant) + pepstatin derivative<br /> | ||
*Plasmepsin IV | *Plasmepsin IV | ||
| Line 39: | Line 42: | ||
**[[2anl]] – Plm IV + statine derivative – ''Plasmodium malariae''<br /> | **[[2anl]] – Plm IV + statine derivative – ''Plasmodium malariae''<br /> | ||
**[[1ls5]] - PfPlm IV + pepstatin derivative<br /> | **[[1ls5]] - PfPlm IV + pepstatin derivative<br /> | ||
*Plasmepsin V or aspartic protease PM5 | |||
**[[6c4g]] – PvPlm V + inhibitor<br /> | |||
**[[4zl4]] – PvPlm V + transition state analog<br /> | |||
*Plasmepsin X | |||
**[[7ry7]] – PvPlm X <br /> | |||
**[[7tbc]], [[7tbd]], [[7tbe]], [[8dsr]] – PfPlm X + inhibitor<br /> | |||
**[[7tbb]] – PfPlm X <br /> | |||
*Proplasmepsin II | |||
**[[1pfz]], [[5bwy]] - PfProPlm II<br /> | |||
**[[1miq]] – PvProPlm II – ''Plasmodium vivax''<br /> | |||
**[[1qs8]], [[5i70]] - PvPlm II + pepstatin derivative<br /> | |||
}} | }} | ||
== References == | |||
<references/> | |||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||